Literature DB >> 6470486

Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.

V W Hu, M L Shin.   

Abstract

The cytolytic efficiency of the terminal complement complex (C5b-9) against erythrocytes of different species is, in part, dependent on the species of C9 origin. In the present study, we have examined the interaction of C9 with erythrocytes in terms of the binding, dimerization, and insertion of C9 into the membranes of sheep and human erythrocytes lysed by human complement (C). The membranes of these C-lysed erythrocytes were analyzed for bound, dimerized, and inserted C9 by a combination of photolabeling, SDS-PAGE, electroblotting, and immunostaining techniques. We found that neither binding nor dimerization of C9 could be correlated with the relative hemolytic efficiency of human C on these erythrocytes, but that C9 insertion into the membranes of these cells varied in direct relation to the extent of lysis. Interestingly, the binding of C3 to these cells under conditions of equivalent C1 fixation also correlated with lytic efficiency. These data indicate that the C9-related differences in the cytolytic efficiency of C against erythrocytes from different species is primarily due to the efficiency of C9 insertion into these cells. Moreover, these data emphasize that neither the binding of C9 to a target membrane nor the formation of C9 dimers necessarily leads to the insertion of C9 into the membrane, suggesting the presence of membrane-bound but inactive C5b-9 complexes. Because the extent of C3 binding also correlated with the relative degree of lysis of sheep vs human erythrocytes, the possibility exists that surface-bound C3 may regulate hemolysis by directing the insertion of C9 in terminal complexes into cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470486

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  C8 binding protein bears I antigenic determinants.

Authors:  P Blaas-Mautner; S Filsinger; B Berger; D Roelcke; G M Hänsch
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

2.  The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.

Authors:  S Schönermark; S Filsinger; B Berger; G M Hänsch
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

3.  Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.

Authors:  M E Medof; T Kinoshita; R Silber; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

4.  Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.

Authors:  V W Hu; A Nicholson-Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

5.  Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  M E Medof; A Gottlieb; T Kinoshita; S Hall; R Silber; V Nussenzweig; W F Rosse
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

6.  Resistance of cytolytic lymphocytes to perforin-mediated killing. Lack of correlation with complement-associated homologous species restriction.

Authors:  S B Jiang; P M Persechini; A Zychlinsky; C C Liu; B Perussia; J D Young
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

7.  CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.

Authors:  A Davies; D L Simmons; G Hale; R A Harrison; H Tighe; P J Lachmann; H Waldmann
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.